TNFSF13B and lobular neoplasia: Blisibimod, a novel monoclonal antibody against BAFF, is being evaluated in both LN and IgAN across several early and late phase trials (NCT02052219, NCT02062684, NCT01395745, NCT02074020, NCT02514967, NCT01305746, NCT01162681).